Herbert Tilg

Herbert Tilg's AcademicInfluence.com Rankings

Herbert Tilg

Physics

#2582

World Rank

#3787

Historical Rank

physics Degrees

Download Badge

Physics

Herbert Tilg's Degrees

PhD Physics University of Vienna
Masters Physics University of Vienna
Bachelors Physics University of Vienna

Why Is Herbert Tilg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Herbert Tilg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Adipocytokines: mediators linking adipose tissue, inflammation and immunity (2006) (2903)
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis (2010) (1881)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. (2016) (1859)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1 Diagnosis and Medical Management (2017) (1353)
XBP1 Links ER Stress to Intestinal Inflammation and Confers Genetic Risk for Human Inflammatory Bowel Disease (2008) (1265)
Intestinal permeability – a new target for disease prevention and therapy (2014) (1113)
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. (2009) (950)
Cytokines in alcoholic and nonalcoholic steatohepatitis. (2000) (929)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. (2010) (883)
Visfatin, an Adipocytokine with Proinflammatory and Immunomodulating Properties1 (2007) (861)
Gut microbiome development along the colorectal adenoma–carcinoma sequence (2015) (853)
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. (1994) (812)
Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. (2004) (796)
Gut microbiome, obesity, and metabolic dysfunction. (2011) (741)
Serum levels of cytokines in chronic liver diseases. (1992) (734)
European consensus conference on faecal microbiota transplantation in clinical practice (2017) (705)
Inflammatory Mechanisms in the Regulation of Insulin Resistance (2008) (698)
Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases (2017) (682)
Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer (2015) (673)
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. (1997) (662)
NAFLD and diabetes mellitus (2017) (605)
Microbiota and diabetes: an evolving relationship (2014) (572)
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. (2001) (552)
Development of the Crohn's disease digestive damage score, the Lémann score (2010) (511)
The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. (2016) (509)
European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis (2006) (500)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. (2013) (477)
Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. (2003) (477)
The intestinal microbiota fuelling metabolic inflammation (2019) (434)
The Intestinal Microbiota in Colorectal Cancer. (2018) (432)
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. (2004) (430)
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. (2007) (426)
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. (2009) (410)
Adiponectin and its receptors in non-alcoholic steatohepatitis (2004) (410)
Insulin resistance, inflammation, and non-alcoholic fatty liver disease (2008) (407)
A guiding map for inflammation (2017) (402)
Antibiotics as deep modulators of gut microbiota: between good and evil (2016) (396)
Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. (2006) (362)
Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease (2017) (349)
Gut microbiome and liver diseases (2016) (327)
Gut, inflammation and osteoporosis: basic and clinical concepts (2008) (269)
Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells (1993) (267)
Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. (2008) (256)
International consensus conference on stool banking for faecal microbiota transplantation in clinical practice (2019) (236)
Faecal calprotectin indicates intestinal inflammation in COVID-19 (2020) (234)
Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. (2010) (232)
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications (2020) (231)
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting (2018) (225)
Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor α expression (2010) (217)
The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss (2005) (214)
Gut microbiome and health: mechanistic insights (2022) (213)
New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. (1997) (213)
Food, immunity, and the microbiome. (2015) (212)
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus (2013) (210)
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. (2003) (209)
Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations. (2016) (207)
Lipocalin-2: A Master Mediator of Intestinal and Metabolic Inflammation (2017) (206)
The Role of Cytokines in Non-Alcoholic Fatty Liver Disease (2010) (205)
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease (2016) (205)
Interleukin‐1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (2016) (205)
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ (2002) (201)
Association of the COVID-19 pandemic with Internet Search Volumes: A Google TrendsTM Analysis (2020) (199)
Increased Expression of CCL20 in Human Inflammatory Bowel Disease (2004) (191)
CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. (2005) (189)
Obesity and the microbiota. (2009) (185)
IL-37 protects against obesity-induced inflammation and insulin resistance (2014) (184)
Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes (2016) (178)
Inflammation, Cytokines and Insulin Resistance: A Clinical Perspective (2013) (175)
Erythropoietin Contrastingly Affects Bacterial Infection and Experimental Colitis by Inhibiting Nuclear Factor-κB-Inducible Immune Pathways (2011) (174)
Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions (2017) (163)
Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease (2018) (159)
Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. (1996) (158)
Adipose and Liver Expression of Interleukin (IL)-1 Family Members in Morbid Obesity and Effects of Weight Loss (2011) (157)
Dietary Factors: Major Regulators of the Gut's Microbiota (2012) (156)
COVID-19 and the gastrointestinal tract: more than meets the eye (2020) (155)
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals (2020) (153)
Management strategies in alcoholic liver disease (2007) (150)
A Role for Low Hepatic Copper Concentrations in Nonalcoholic Fatty Liver Disease (2010) (148)
Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. (2004) (144)
Non-alcoholic steatohepatitis: a microbiota-driven disease (2013) (143)
Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH (2021) (140)
Induction of circulating IL-1 receptor antagonist by IFN treatment. (1993) (130)
The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. (2005) (130)
Role of IL-10 for Induction of Anemia During Inflammation1 (2002) (129)
Higher spermidine intake is linked to lower mortality: a prospective population-based study. (2018) (128)
Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. (2009) (122)
Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. (2010) (121)
Imbalance between interleukin‐1 agonists and antagonists: relationship to severity of inflammatory bowel disease (2004) (120)
From NAFLD to MAFLD: when pathophysiology succeeds (2020) (120)
ER stress transcription factor Xbp1 suppresses intestinal tumorigenesis and directs intestinal stem cells (2013) (119)
Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. (1990) (117)
How to modulate inflammatory cytokines in liver diseases (2006) (115)
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report (2022) (115)
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. (2021) (115)
Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel (2020) (115)
A role for IL-16 in the cross-talk between dendritic cells and T cells. (1999) (114)
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade (2020) (112)
Obesity, Metabolic Syndrome, and Microbiota: Multiple Interactions (2010) (111)
Silymarin: A Review of its Clinical Properties in the Management of Hepatic Disorders (2001) (110)
Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma (2017) (109)
American Journal of Physiology: Gastrointestinal and Liver Physiology American Journal of Physiology: Heart and Circulatory Physi- QlQgY American Journal of Physiology: Regulatory, Integrative and Comparative Physiology American Journal of Physiology: Renal, Fluid and Electrolyte (2003) (108)
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III) (2017) (104)
Cutting Edge: Peripheral Neuropeptides Attract Immature and Arrest Mature Blood-Derived Dendritic Cells1 (2001) (103)
The RANKL/OPG system and bone mineral density in patients with chronic liver disease. (2005) (102)
Gut microbiome, liver immunology, and liver diseases (2020) (101)
Effect of bariatric surgery on circulating chemerin levels (2010) (98)
Liver-Microbiome Axis in Health and Disease. (2018) (97)
Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. (2004) (96)
Adiponectin and its receptors in patients with chronic hepatitis C. (2005) (95)
B Lymphocyte-Derived IL-16 Attracts Dendritic Cells and Th Cells1 (2000) (95)
Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. (2013) (95)
A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. (2010) (94)
Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. (2006) (94)
Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression. (1999) (92)
Nonalcoholic fatty liver disease and hepatocellular carcinoma. (2016) (92)
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis (2020) (90)
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic (2020) (90)
Cytokines and liver diseases. (2001) (90)
In-vitro and in-vivo studies on the induction of neopterin biosynthesis by cytokines, alloantigens and lipopolysaccharide (LPS). (1988) (90)
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. (2011) (86)
Clinical presentation of venous thromboembolism in inflammatory bowel disease. (2013) (85)
Plasma Levels of Interleukin-18 and Interleukin-18 Binding Protein Are Elevated in Patients with Chronic Liver Disease (2002) (85)
A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis (2003) (84)
Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. (2001) (84)
Adiponectin: key player in the adipose tissue-liver crosstalk. (2012) (83)
Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis (2005) (82)
Pathways of liver injury in alcoholic liver disease. (2011) (81)
NAD metabolism fuels human and mouse intestinal inflammation (2017) (81)
Circulating interleukin‐1 and tumor necrosis factor antagonists in liver disease (1993) (80)
Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation. (1990) (79)
Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration (2014) (79)
Dietary lipids fuel GPX4-restricted enteritis resembling Crohn’s disease (2020) (79)
Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. (2005) (78)
Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. (2010) (78)
Interferon-alpha controls IL-17 expression in vitro and in vivo. (2008) (78)
Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans. (1994) (76)
Adipose Tissue Inflammation (2014) (76)
Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. (1992) (76)
Interleukin‐32: A new proinflammatory cytokine involved in hepatitis C virus‐related liver inflammation and fibrosis (2011) (74)
Global multi-stakeholder endorsement of the MAFLD definition. (2022) (74)
Adiponectin: a key fat-derived molecule regulating inflammation (2005) (72)
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies (2021) (72)
Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease. (2016) (71)
Calprotectin: from biomarker to biological function (2021) (69)
Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk (2016) (69)
Treatment strategies in nonalcoholic fatty liver disease (2005) (68)
CD40 Ligand-Dependent Maturation of Human Monocyte-Derived Dendritic Cells by Activated Platelets (2003) (66)
Cheilitis granulomatosa and Melkersson–Rosenthal syndrome: evaluation of gastrointestinal involvement and therapeutic regimens in a series of 14 patients (2007) (66)
Influence of Visceral Obesity and Liver Fat on Vascular Structure and Function in Obese Subjects (2009) (65)
Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. (2005) (64)
Cytokines and fatty liver diseases (2018) (64)
Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent Clostridioides difficile Infection Treated With Fecal Microbiota Transplantation or Antibiotics (2019) (64)
Mechanisms behind the link between obesity and gastrointestinal cancers. (2014) (63)
Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases (2022) (63)
Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. (2007) (63)
IMMUNE RESPONSE MODULATION BY PENTOXIFYLLINE IN VITRO (1993) (62)
Engagement of the FcεRI Stimulates the Production of IL-16 in Langerhans Cell-Like Dendritic Cells1 2 (2001) (62)
The effect of zoledronic acid on the function and differentiation of myeloid cells. (2006) (61)
Dietary spermidine improves cognitive function. (2021) (60)
Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases (2003) (60)
Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis. (2010) (59)
Gut Dysfunction and Non-alcoholic Fatty Liver Disease (2019) (59)
Systemic inflammation as fuel for acute liver injury in COVID-19 (2020) (57)
CYCLOSPORIN BLOOD LEVELS DO CORRELATE WITH CLINICAL COMPLICATIONS (1984) (56)
Clinical Implementation of Prolonged Liver Preservation and Monitoring Through Normothermic Machine Perfusion in Liver Transplantation (2020) (56)
Role for hedgehog pathway in regulating growth and function of invariant NKT cells (2009) (56)
Gender and age specific differences in exhaled isoprene levels (2006) (56)
Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases (2007) (55)
Telomere length increase after weight loss induced by bariatric surgery: results from a 10 year prospective study (2016) (55)
Adipose type I interferon signalling protects against metabolic dysfunction (2016) (55)
Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver. (2013) (54)
Incidence of Gallstone Formation and Cholecystectomy 10 Years After Bariatric Surgery (2015) (54)
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial (2021) (53)
Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: report of a phase I trial in bone marrow transplant recipients. (1991) (53)
B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19 (2021) (52)
Association between non‐alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta‐analysis (2019) (51)
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity (2021) (51)
A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group (2020) (51)
Interferon‐α induces interleukin‐18 binding protein in chronic hepatitis C patients (2002) (50)
A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. (2003) (50)
Lipocalin‐2 ensures host defense against Salmonella Typhimurium by controlling macrophage iron homeostasis and immune response (2015) (50)
Effects of Pronounced Weight Loss on Adiponectin Oligomer Composition and Metabolic Parameters (2007) (50)
Influence of the human intestinal microbiome on obesity and metabolic dysfunction (2015) (49)
Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. (2010) (49)
Heterozygosity for the alpha‐1‐antitrypsin Z allele in cirrhosis is associated with more advanced disease (2018) (47)
Long‐term effects of weight loss after bariatric surgery on functional and structural markers of atherosclerosis (2013) (46)
Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon‐gamma (IFN‐γ) (1991) (46)
Heterogeneity of fibrosis patterns in non‐alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways (2010) (44)
Interleukin-16 supports the migration of Langerhans cells, partly in a CD4-independent way. (2001) (43)
Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease. (2010) (43)
A Gut Feeling about Thrombosis. (2016) (43)
Role of IL-10 for Induction of Anemia During Inflammation (2002) (42)
Comparison of serum neopterin levels and urinary neopterin excretion in renal allograft recipients. (1988) (41)
Visceral adipose tissue attacks beyond the liver: esophagogastric junction as a new target. (2010) (41)
Circulating serum levels of interleukin 6 and C-reactive protein after liver transplantation. (1992) (41)
Telomere length of in vivo expanded CD4+CD25+ regulatory T-cells is preserved in cancer patients (2006) (41)
Effect of pronounced weight loss on visceral fat, liver steatosis and adiponectin isoforms (2008) (40)
Interleukin-8 serum concentrations after liver transplantation. (1992) (39)
Food, microbiome and colorectal cancer. (2018) (39)
Nutrition in Inflammatory Bowel Disease (2020) (39)
NAFLD and extrahepatic cancers: have a look at the colon (2011) (38)
Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans. (1994) (38)
Sphingosine Kinase-Dependent Migration of Immature Dendritic Cells in Response to Neurotoxic Prion Protein Fragment (2003) (38)
Pharmacological and non‐pharmacological treatment of non‐alcoholic fatty liver disease (2010) (38)
DIFFERENTIAL REGULATION OF INTERLEUKIN 4 AND INTERLEUKIN 13 PRODUCITON BY INTERFERON α (1998) (38)
The role of apolipoprotein A5 in non-alcoholic fatty liver disease (2011) (38)
Liver Complications in Inflammatory Bowel Diseases (2013) (37)
Current therapies and new developments in NASH (2022) (35)
A‐FABP—A Biomarker Associated With the Metabolic Syndrome and/or an Indicator of Weight Change? (2008) (35)
Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions (2015) (34)
Diet and intestinal immunity. (2012) (34)
Influence of significant weight loss on serum matrix metalloproteinase (MMP)-7 levels. (2010) (34)
Excellent post‐transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy (2016) (34)
Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation (2010) (34)
Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects. (1993) (33)
Differential regulation of interleukin 4 and interleukin 13 production by interferon alpha. (1998) (33)
A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection (2019) (33)
C-reactive protein levels and post-ICU mortality in nonsurgical intensive care patients. (2010) (33)
Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. (2019) (32)
Interferon-alpha and its effects on the cytokine cascade: a pro- and anti-inflammatory cytokine. (1996) (32)
Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera. (1993) (32)
Nuclear Receptors Regulate Intestinal Inflammation in the Context of IBD (2019) (32)
Characterization of the B Cell Receptor Repertoire in the Intestinal Mucosa and of Tumor-Infiltrating Lymphocytes in Colorectal Adenoma and Carcinoma (2017) (31)
Microbial butyrate synthesis indicates therapeutic efficacy of azathioprine in IBD patients. (2020) (31)
Adipocytokines and Hepatocellular Carcinoma (2012) (31)
Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome (2016) (31)
Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis (2020) (31)
Interferon-β1b augments activation-induced T-cell death in multiple sclerosis patients (1999) (31)
Translating the gut microbiome: ready for the clinic? (2019) (31)
Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors (2016) (31)
Diet and relapsing ulcerative colitis: take off the meat? (2004) (31)
IL-1 cytokine family members and NAFLD: neglected in metabolic liver inflammation. (2011) (30)
Soluble HLA class I serum concentrations increase with transplant-related complications after liver transplantation. (1992) (30)
Dendritic cell migration in different micropore filter assays. (2000) (29)
Static cold storage compared with normothermic machine perfusion of the liver and effect on ischaemic-type biliary lesions after transplantation: a propensity score-matched study. (2021) (29)
Transcription factor Fra‐1 induces cholangitis and liver fibrosis (2011) (29)
H. pylori Infection Increases Levels of Exhaled Nitrate (2005) (29)
Indications for liver transplantation in adults (2016) (28)
Intravenous iron supplementation therapy. (2020) (28)
Endotoxin and its binding proteins in chronic liver disease: the effect of transjugular intrahepatic portosystemic shunting. (2002) (28)
Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C (2006) (28)
Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. (2020) (28)
A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapy. (1993) (28)
Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018 (2020) (27)
Transferrin as a predictor of survival in cirrhosis (2018) (27)
Metabolic effects of reduced growth hormone action in fatty liver disease (2018) (26)
Metabolomic analysis-Addressing NMR and LC-MS related problems in human feces sample preparation. (2017) (26)
The kinase inhibitor imatinib--an immunosuppressive drug? (2007) (25)
Roseburia hominis: a novel guilty player in ulcerative colitis pathogenesis? (2013) (25)
Engagement of the Fc epsilon RI stimulates the production of IL-16 in Langerhans cell-like dendritic cells. (2001) (25)
Neopterin excretion after liver transplantation and its value in differential diagnosis of complications. (1989) (25)
Fecal biomarkers in inflammatory bowel diseases: calprotectin versus lipocalin-2 - a comparative study. (2020) (24)
Interferon-alpha in inflammation and immunity. (2001) (24)
Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial. (1991) (24)
Infliximab and alcoholic hepatitis (2004) (24)
Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy. (1995) (23)
Prebiotic Effects of Partially Hydrolyzed Guar Gum on the Composition and Function of the Human Microbiota—Results from the PAGODA Trial (2020) (23)
Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes. (2017) (23)
Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and Interleukin 2 (1991) (23)
Serum neopterin concentrations in chronic liver disease. (1995) (22)
Fat-enriched rather than high-fructose diets promote whitening of adipose tissue in a sex-dependent manner. (2017) (22)
Innate Immunity in Gastrointestinal Disorders: Basic and Therapeutic Concepts (2012) (22)
Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis. (2019) (22)
Prospective multicentre clinical study on inter- and intrapatient genetic variability for antimicrobial resistance of Helicobacter pylori. (2017) (22)
Interferon-a Stimulates Production of Interleukin-10 in Activated CD4+ T Cells and Monocytes (2002) (22)
Liver tissue microbiome in NAFLD: next step in understanding the gut–liver axis? (2020) (22)
Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro. (1994) (22)
Pancreas-Microbiota Cross Talk in Health and Disease. (2019) (21)
Dynamics of Bile Acid Profiles, GLP-1, and FGF19 After Laparoscopic Gastric Banding (2017) (21)
Neurokinin-1 receptor interacts with PrP106–126-induced dendritic cell migration and maturation (2005) (21)
A key role for Pre–B cell colony–enhancing factor in experimental hepatitis (2011) (21)
Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. (2002) (21)
Type I interferons and their therapeutic role in Th2-regulated inflammatory disorders (2004) (21)
Biologic activity of low dosage IL-2 treatment in vivo. Molecular assessment of cytokine network interaction. (1994) (21)
Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer. (1989) (20)
"Metabolic aspects" in inflammatory bowel diseases. (2012) (20)
Decline in acute upper gastrointestinal bleeding during COVID-19 pandemic after initiation of lockdown in Austria (2020) (20)
Interferons and their role In inflammation. (1999) (20)
Recombinant interferon-alpha-2C in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response. (1990) (19)
Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up (2004) (19)
Anti-TNF antibody in Crohn's disease--status of information, comments and recommendations of an international working group. (1999) (19)
COVID-19 and liver disease (2022) (19)
Endogenous interleukin 1 receptor antagonist during human bone marrow transplantation: increased levels during graft-versus-host disease, during infectious complications, and after immunoglobulin therapy. (1997) (18)
The role of lipocalin‐2 in liver regeneration (2015) (18)
Beyond Digestion: The Pancreas Shapes Intestinal Microbiota and Immunity. (2017) (18)
Nuclear orphan receptor NR2F6 as a safeguard against experimental murine colitis (2017) (18)
Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: Results of phase 2a trial. (2021) (18)
Gut microbiota: Malnutrition and microbiota—a new relationship? (2013) (18)
The role of cytokines in the pathophysiology of chronic liver diseases. (1993) (18)
Anti-inflammatory effects of hepatocyte growth factor: induction of interleukin-1 receptor antagonist. (2004) (17)
Liver stiffness by transient elastography accompanies illness severity in COVID-19 (2020) (17)
Suppression of interleukin-17 by type I interferons: a contributing factor in virus-induced immunosuppression? (2009) (17)
Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy. (1999) (17)
Targeting T and B Lymphocytes in Inflammatory Bowel Diseases: Lessons from Clinical Trials (2013) (17)
A biological approach to optimize interferon treatment in hairy cell leukemia. (1986) (17)
Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease (2008) (17)
Novel therapeutic targets in the treatment of IBD (2008) (16)
The metabolic nature of inflammatory bowel diseases (2022) (16)
Enhanced Serum Levels of β-2-Microglobulin, Neopterin, and Interferon-γ in Patients Treated with Recombinant Tumor Necrosis Factor-α (1988) (16)
Headspace screening of fluid obtained from the gut during colonoscopy and breath analysis by proton transfer reaction-mass spectrometry: A novel approach in the diagnosis of gastro-intestinal diseases (2005) (16)
Validation of the ‘Inflammatory Bowel Disease—Distribution, Chronicity, Activity [IBD-DCA] Score’ for Ulcerative Colitis and Crohn´s Disease (2021) (16)
Ganciclovir and hyperimmunoglobulin for treating cytomegalovirus infection in bone marrow transplant recipients. (1988) (16)
Paneth Cells and their Antimicrobials in Intestinal Immunity. (2018) (16)
Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patients. (1989) (16)
NAFLD-related mortality: simple hepatic steatosis is not as ‘benign’ as thought (2020) (16)
Circulating Wnt inhibitory factor 1 levels are associated with development of cardiovascular disease. (2018) (15)
Cachexia and tumour necrosis factor-alpha in cytomegalovirus infection. (1991) (15)
Heart rate before ICU discharge: a simple and readily available predictor of short- and long-term mortality from critical illness (2013) (15)
Mediator-dependent effects of pentoxifylline on endothelium for transmigration of neutrophils. (1999) (15)
Gut-liver axis: Pathophysiological concepts and clinical implications. (2022) (15)
Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease (2020) (15)
Impaired counter-regulation of interleukin-1 by the soluble IL-1 receptor type II in patients with chronic liver disease (2008) (15)
Evolving therapies for non-alcoholic steatohepatitis (2014) (15)
Short bowel syndrome: searching for the proper diet (2008) (15)
Proinflammatory wheat attacks on the intestine: alpha-amylase trypsin inhibitors as new players. (2013) (15)
Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease (2019) (15)
Modulation of Liver Inflammation and Fibrosis by Interleukin-37 (2021) (14)
Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. (2021) (14)
A randomised placebo controlled trial of pegylated interferon α in active ulcerative colitis (2003) (14)
Activation of caspase-3 by interferon alpha causes interleukin-16 secretion but fails to modulate activation induced cell death. (2001) (14)
PUFA-induced metabolic enteritis as a fuel for Crohn's disease. (2022) (14)
Failure of interleukin 13 blockade in ulcerative colitis (2015) (14)
The role of gut vascular barrier in experimental alcoholic liver disease and A. muciniphila supplementation (2020) (14)
Effect of weight loss on serum pigment epithelium‐derived factor levels (2011) (13)
Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity (2020) (13)
Analysis of Volatile Compounds Emitted by the Helicobacter pylori Reference Strain NCTC 11637 In Vitro (2006) (13)
Altered intestinal microbiota as a major driving force in alcoholic steatohepatitis (2016) (13)
A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)? (2020) (13)
Weight loss induced by bariatric surgery restores adipose tissue PNPLA3 expression (2017) (13)
Novel therapeutic targets in the treatment of IBD. (2008) (13)
In vivo effects of recombinant human interleukin-10 on lymphocyte phenotypes and leukocyte activation markers in inflammatory bowel disease. (2000) (12)
Ethanol‐mediated suppression of IL‐37 licenses alcoholic liver disease (2018) (12)
Cruciferous vegetables: prototypic anti-inflammatory food components (2015) (12)
Gut Microbiome, Obesity, and Metabolic Syndrome (2015) (12)
Increased Fecal Neopterin Parallels Gastrointestinal Symptoms in COVID-19 (2021) (12)
Compared to 123I-MIBG SPECT/CT, 18F-DOPA PET/CT provides accurate tumor extent in patients with extra-adrenal paraganglioma (2017) (12)
Bile acids as modulators of gut microbiota linking dietary habits and inflammatory bowel disease: a potentially dangerous liaison. (2013) (12)
Treatment of Cancer Patients with Recombinant Interferon-γ Induces Release of Endogenous Tumor Necrosis Factor-α (1990) (12)
Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia. (1987) (11)
Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients. (1999) (11)
[113] PROGRESSIVE FIBROSIS IN NON-ALCOHOLIC STEATOHEPATITIS - ASSOCIATION WITH ALTERED REGENERATION AND A DUCTULAR REACTION (2007) (11)
Clinical and cytokine response to anti-TNF antibody therapy in severe alcoholic hepatitis. (2001) (11)
The impact of prolonged strenuous endurance exercise on interleukin 18 and interleukin 18 binding protein in recreational cyclists. (2005) (11)
Adiponectin and JNK: metabolic/inflammatory pathways affecting gastrointestinal carcinogenesis (2009) (11)
Predicting mortality by the Glasgow alcoholic hepatitis score: the long awaited progress? (2005) (11)
Serum Prolactin in Advanced Chronic Liver Disease (2014) (11)
Metabolic recovery after weight loss surgery is reflected in serum microRNAs (2020) (11)
PREOPERATIVE ASSESSMENT OF MUSCLE MASS USING COMPUTERIZED TOMOGRAPHY SCANS TO PREDICT OUTCOMES FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION. (2019) (10)
Weight Loss Induced by Bariatric Surgery Restricts Hepatic GDF15 Expression (2018) (10)
Relevance of TNF-α gene polymorphisms in nonalcoholic fatty liver disease (2011) (9)
Recombinant human interleukin-10 (rHuIL-10) therapy in steroid-refractory chronic active Crohn's disease (CACD): Induction of neopterin, a degradation product of the pteridine pathway regulated by interferon-gamma (1998) (9)
ABO-incompatible renal transplantation: report of two transplants from AB donors to A recipients. (1987) (9)
Helicobacter pylori infection, iNOS, and gastric cancer: The impact of another possible link (2007) (8)
High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation (2019) (8)
Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study (2019) (8)
Gut—Liver Interactions: Basic and Clinical Concepts (2006) (8)
Cardioprotective effects of short-term empagliflozin treatment in db/db mice (2020) (8)
[Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH]. (2006) (8)
Clinical challenges and images in GI. Pill esophagitis. (2006) (8)
Correction: Corrigendum: IL-37 protects against obesity-induced inflammation and insulin resistance (2015) (8)
Dietary saturated lipids in alcoholic liver disease: new microbiota-targeting bullets? (2015) (8)
Recovery of Bacteroides thetaiotaomicron ameliorates hepatic steatosis in experimental alcohol-related liver disease (2022) (7)
Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes-The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. (2021) (7)
Circulating interleukin-1 receptor antagonist levels in neonates (1996) (7)
Colorectal cancer screening and prevention—pros and cons (2019) (7)
Pancreatic juice neopterin excretion--a reliable marker of pancreas allograft rejection. (1992) (7)
[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations (Spanish version)]. (2015) (6)
Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia (1993) (6)
Adipocyte GPX4 protects against inflammation, hepatic insulin resistance and metabolic dysregulation (2022) (6)
Interferon-alpha suppresses leptin levels: studies in interferon-alpha treated patients with hepatitis C virus infection and murine adipocytes. (2002) (6)
Too much fat for the gut's microbiota (2012) (6)
How to Approach a Patient With Nonalcoholic Fatty Liver Disease. (2017) (6)
SARS-CoV-2 vaccines and donor recruitment for FMT (2021) (6)
Acute phase response after myocardial infarction: Correlation between serum levels of cytokines and C-reactive protein (1990) (6)
Prebiotics for obesity: a small light on the horizon? (2013) (6)
W1138 A Nationwide Multicenter Study On Venous Thromboembolism in Inflammatory Bowel Disease (2008) (6)
How does the microbiome affect liver disease? (2016) (6)
IL:32: A new pro-inflammatory cytokine involved in HCV-related liver inflammation and fibrosis (2009) (6)
Prescription of oral antidiabetic drugs in Tyrol – Data from the Tyrol diabetes registry 2012–2015 (2016) (6)
Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease (2020) (6)
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. (2022) (6)
Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals (2022) (6)
Serum colony stimulating factors in patients undergoing bone marrow transplantation: enhancing effect of recombinant human GM-CSF. (1988) (6)
Live Confocal Imaging as a Novel Tool to Assess Liver Quality: Insights From a Murine Model (2020) (6)
Plasma levels of atrial natriuretic peptide and tumor necrosis factor-α during transient myocardial ischemia in patients with stable angina (1991) (5)
Splanchnic blood flow determination in patients with suspected chronic intestinal ischaemia (2002) (5)
Controversy over NOD2, inflammation, and defensins. (2010) (5)
12: IL-37 protects against obesity-induced inflammation and insulin resistance (2013) (5)
Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals (2022) (5)
Highly Elevated Plasma γ‐Glutamyltransferase Elevations: A Trait Caused by γ‐Glutamyltransferase 1 Transmembrane Mutations (2019) (5)
Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030 (2018) (5)
[Immunosuppressive therapy for inflammatory bowel disease: consensus by the Austrian working group on IBD]. (2004) (5)
Livedo Racemosa – The Pathophysiology of Decompression-Associated Cutis Marmorata and Right/Left Shunt (2020) (4)
Gastric banding-associated weight loss diminishes hepatic Tsukushi expression (2020) (4)
MRI‐Based Iron Phenotyping and Patient Selection for Next‐Generation Sequencing of Non–Homeostatic Iron Regulator Hemochromatosis Genes (2021) (4)
Reassessment of Relevance and Predictive Value of Parameters Indicating Early Graft Dysfunction in Liver Transplantation: AST Is a Weak, but Bilirubin and INR Strong Predictors of Mortality (2021) (4)
[Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH]. (2004) (4)
Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic Pharmacokinetics (2021) (4)
IL-6 and arthritis: a detrimental or beneficial mediator? (1998) (4)
Iron Matryoshka—Haemochromatosis nested in Ferroportin Disease? (2019) (4)
Western-diet-derived arachidonic acid induces epithelial ferroptosis which is a feature of Crohn's disease (2019) (4)
Pentoxifylline influences acute-phase response in acute myocardial infarction (1992) (4)
Ethanol-induced depletion of Akkermansia muciniphila drives alcoholic liver disease (2017) (4)
Urinary and pancreatic juice neopterin excretion after combined pancreas-kidney transplantation. (1992) (4)
Coronary atherosclerosis profile in patients with end-stage liver disease prior to liver transplantation due to alcoholic fatty liver: a coronary CTA study (2020) (4)
Minimal interferon-alpha doses for hairy cell leukemia [letter; comment] (1990) (4)
Adipocyte Hypertrophy and Improved Postprandial Lipid Response in Beta 2 Syntrophin Deficient Mice. (2019) (4)
Long-term life history predicts current gut microbiome in a population-based cohort study (2022) (4)
Short‐term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placebo‐controlled, double blind, cross‐over pilot study (2018) (4)
Dose related effectiveness of alpha interferon in chronic myelogenous leukemia (1987) (4)
Uterine microbiota plasticity during the menstrual cycle: Differences between healthy controls and patients with recurrent miscarriage or implantation failure. (2022) (4)
Gut microbiome-immune crosstalk affects progression of cancer. (2018) (3)
Hypophosphatemia after Treatment of Iron Deficiency with Intravenous Ferric Carboxymaltose or Iron Isomaltoside -A Systematic Review and Meta-Analysis (2020) (3)
Cytomegalovirus infection. (2015) (3)
Neurodegeneration in Hepatic and Neurologic Wilson’s Disease (2020) (3)
Apolipoprotein A5 controls fructose-induced metabolic dysregulation in mice. (2020) (3)
The Need to Update Endpoints and Outcome Analysis in the Rapidly Changing Field of Liver Transplantation. (2021) (3)
Hepatocyte growth factor plasma levels after myocardial infarction are not affected by recombinant tissue-type plasminogen-activator therapy. (2000) (3)
Antitumour necrosis factor therapy in Crohn’s disease (2002) (3)
Short- and Long-Term Effects of a Prebiotic Intervention with Polyphenols Extracted from European Black Elderberry—Sustained Expansion of Akkermansia spp. (2022) (3)
Frequencyand outcomes of liver transplantation for nonalcoholic steatohepatitis in Europe (2018) (3)
Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects (2022) (3)
Treatment of cancer patients with recombinant interferon-gamma induces release of endogenous tumor necrosis factor-alpha. (1990) (3)
Effect of Recombinant Interferon Alpha-2 on the Growth of Hematopoetic Progenitor Cells in Chronic Myelogenous Leukemia and Its Relationship to the Clinical Efficacy (1988) (3)
The intestinal microbiota and hepatocellular carcinoma (2020) (3)
Inflammatory bowel diseases: highlights from the United European Gastroenterology Week 2008 (2009) (3)
New insights into the pathogenesis of anemia of chronic diseases: Induction of ferritin synthesis and development of anemia during recombinant human interleukin-10 (rHuIL-10) treatment of chronic active Crohn's disease (CACD)* (1998) (3)
Prognostic significance of hepatic arterial collaterals in liver transplant recipients with biliary strictures (2017) (3)
Abdominal pain beyond IBS. Hereditary angioedema (HAE type III). (2011) (3)
Synonymous mutation in adenosine triphosphatase copper‐transporting beta causes enhanced exon skipping in Wilson disease (2022) (3)
[Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology]. (2009) (3)
Inflammation, Cytokines and Insulin Resistance: A Clinical Perspective (2013) (2)
The inflammatory response in liver injury (2009) (2)
[Nonalcoholic steatohepatitis: epidemiology, diagnosis and treatment]. (2001) (2)
Microbiota and diabetes: an increasingly relevant association. (2018) (2)
Management of ductal pancreatic cancer (2019) (2)
Prospective, multicenter clinical trial on inter- and intra-patient genetic variability for antimicrobial resistance of Helicobacter pylori (2017) (2)
Alcohol Use and Gastrointestinal Disease (2020) (2)
A woman with vomiting and depression (2001) (2)
MAFLD: what 2 years of the redefinition of fatty liver disease has taught us (2022) (2)
Circulating Microrna-122 Is Associated With Incident Metabolic Syndrome and Type-2 Diabetes (2016) (2)
Inflammatory bowel diseases: meeting of the European Crohn’s Colitis Organization (2007) (2)
How to Manage Crohn's Disease After Ileocolonic Resection? (2020) (2)
[Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon]. (1985) (2)
Author Correction: A guiding map for inflammation (2020) (2)
Gut microbiota as gatekeeper of anti-tumour responses in the liver (2018) (2)
Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans (2020) (2)
In vivo changes of lymphocyte subpopulations and leukocyte surface markers by multiple doses of recombinant human interleukin-10 in inflammatory bowel disease (1998) (2)
Interleukin-11 drives human and mouse alcohol-related liver disease (2022) (2)
[Colorectal cancer: screening and surveillance in inflammatory bowel diseases - consensus of the working group for inflammatory bowel diseases of the Austrian Society of Gastroenterology and Hepatology]. (2013) (2)
Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report (2020) (2)
Inflammatory and Anti-Inflammatory Mediators Secreted by Adipose Tissue (2009) (2)
Suppression of thyroid function by interferon-alpha2 in man (1991) (2)
[Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology]. (2011) (2)
Is heterozygosity for the alpha-1 antitrypsin risk allele Pi*MZ disease modifier or genetic risk factor? (2020) (2)
Cytokine production after liver transplantation. (1990) (2)
[Endoscopy in IBD. A Consensus Report of the IBD Working of the Austrian Association of Gastroenterology and Hepatology]. (2006) (2)
Minimal interferon-alpha doses for hairy cell leukemia. (1990) (2)
[Use of infliximab in ulcerative colitis]. (2007) (2)
Evaluation of spontaneous lymphocyte proliferation by single cell autoradiography in human allograft recipients. (1985) (1)
IL-37 correlates with MELD Score & thrombocytopenia in patients with liver cirrhosis (2019) (1)
[Interferon-alpha in the treatment of hematologic neoplasms]. (1986) (1)
Imaging Properties and Tumor Targeting of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients (2022) (1)
Association between GNPAT genotypes and serum iron parameters in C282Y homozygous and C282Y/H63D compound heterozygous patients (2017) (1)
Penetrance, cancer incidence and survival of hemochromatosis in a long-term follow-up and epidemiological modeling study (2020) (1)
UEG Week Vienna 2014 cutting edge symposium: Today’s Science, Tomorrow’s Medicine session features the immune system – a driving force in digestive health and disease (2014) (1)
154 ER Stress Transcription Factor XBP1 Suppresses Intestinal Tumorigenesis (2013) (1)
Enhanced serum levels of beta-2-microglobulin, neopterin, and interferon-gamma in patients treated with recombinant tumor necrosis factor-alpha. (1988) (1)
Serum levels of soluble CD40 ligand (CD154) are elevated in patients with inflammatory bowel disease (2000) (1)
Mitochondrial respiration during normothermic liver machine perfusion predicts clinical outcome (2022) (1)
Gemcitabine related pneumonitis (GRP) in patients with pancreatic ductal adenocarcinoma (PDAC) – A case series (2019) (1)
[Second Austrian consensus on the safe use of anti-TNFα-antibodies in patients with inflammatory bowel diseases]. (2018) (1)
How our understanding of the microbiome has changed the way we look at liver diseases. (2018) (1)
Akkermansia Muciniphila Protects from Alcoholic Liver Disease (2016) (1)
Immunomodulatory and antiviral effects of natural interleukin-2 in patients with chronic hepatitis B (1990) (1)
Expanding the clinical and molecular spectrum of ferroportin disease (2017) (1)
Bosentan treatment in chronic pulmonary venous hypertension with significant right heart dysfunction (2007) (1)
Ultra-rapid rollout vaccination with BNT162b2 to reduce SARS-CoV-2 infections in the general population (2022) (1)
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease (2023) (1)
Stress proteins and myocardial protection: is there a role for tumour necrosis factor? (1991) (1)
Using Infodemiology Metrics to Assess Public Interest in Liver Transplantation: Google Trends Analysis (2021) (1)
Letter of Thanks for UEG Week 2020 Reviewers (2020) (1)
Abstract 17961: Circulating MicroRNA-122 is Associated With Incident Metabolic Syndrome and Type-2-diabetes (2015) (1)
What's Hot in the Red Journal This Month? (2010) (1)
Adipose tissue and liver expression of PROGRANULIN after extensive weight loss in morbid obesity (2014) (1)
Treatment With α-1-Antitrypsin for Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease: A Report of 2 Cases. (2016) (1)
Clinical update on inflammatory disorders of the gastrointestinal tract. (2009) (1)
Multiple cerebral lesions in a patient with refractory celiac disease: A case report (2020) (1)
Inflammatory bowel diseases: highlights from the United European Gastroenterology Week 2008. (2009) (1)
Is There Decreasing Public Interest in Renal Transplantation? A Google TrendsTM Analysis (2020) (1)
Lipocalin2 deficiency results in colitis exacerbation and tumor development in IL-10 mice by Alistipes overgrowth (2016) (1)
Hepatic Meteorin-like and Krüppel-like Factor 3 are Associated with Weight Loss and Liver Injury. (2021) (1)
Liver microbes controlling immunity: Facts and pitfalls. (2022) (1)
[Gas gangrene as a manifestation of endogenous Clostridium septicum infection]. (1995) (1)
Crohn ’ s Disease – a Practical Guideline : Actualised Consensus of the Working Group for Chronic Inflammatory Bowel Diseases of the Austrian Society for Gastroenterology and Hepatology (2011) (0)
24-Norursodeoxycholic acid ameliorates experimental alcoholic liver disease in both preventive and therapeutic settings (2022) (0)
Gene expression studies in skeletal muscle and myocardium in a mouse model of iron deficiency (2022) (0)
Interferon alpha upregulates Fas and Fas ligand expression and causes apoptosis in leukocytes from healthy volunteers and patients with chronic HCV infection (1998) (0)
Lipocalin2 protects from severe inflammation in IL-10 knockout mice (2015) (0)
P189 VISFATIN - A NOVEL MEMBER OF THE ADIPOCYTOKINE FAMILY IS ACTIVATED IN INFLAMMATORY BOWEL DISEASE (2007) (0)
Targeting the Role of IL-37 in ALD (2017) (0)
Cloak and dagger ‐ secondary hemophygocytic lymphohistiocytosis caused by intravenous autoinfection (2019) (0)
1950-P: Effects of Dietary Composition on Intestinal Glucocorticoid Receptor Signaling (2019) (0)
High pre-test likelihood for non-HFE mutations through full exome sequencing in patients with hepatic iron overload (2019) (0)
Overexpression of macrophage migratory inhibitory factor (MIF) in human inflammatory bowel disease (IBD) (2001) (0)
Corrigendum to “IL-1 cytokine family members and NAFLD: Neglected in metabolic liver inflammation” [J Hepatol 2011;55:960–962] (2012) (0)
Colorectal Adenoma and Carcinoma Tumor-Infiltrating Lymphocytes in Repertoire in the Intestinal Mucosa and of Characterization of the B Cell Receptor (2017) (0)
PReS13-SPK-1292: Gut microbiome and metabolism (2013) (0)
P917 Intestinal complement interacts with commensal microbiota and provides pattern recognition in Inflammatory Bowel Disease (2023) (0)
Cytokine productio after liver transplantation (1990) (0)
The Phenotypic Spectrum of Patients with Genetic variants in Ceruloplasmin (2021) (0)
Dietary lipids fuel GPX4-restricted enteritis resembling Crohn’s disease (2020) (0)
Elevated levels of soluble interleukin-1-receptor type I, but not type II in patients with inflammatory bowel disease (2000) (0)
Telomerase Activity and Telomere Length of CD4+CD25+ Regulatory T-Cells under Conditions of In Vitro and In Vivo Expansion. (2004) (0)
Alpha1-antitrypsin inhibits secretion of Fas ligand in human mononuclear cells by affecting Fas ligand processing (1998) (0)
EP1272: DIETARY LIPIDS FUEL METABOLIC ENTERITIS IN CROHN'S DISEASE (2022) (0)
Reply (2019) (0)
Bone marker response to intravenous iron treatment - an in vitro model (2021) (0)
REASSESSMENT OF THE RELEVANCE AND PREDICTIVE VALUE OF PARAMETERS INDICATING EARLY GRAFT DYSFUNCTION IN LIVER TRANSPLANTATION: A RETROSPECTIVE SINGLE CENTER EXPERIENCE (2020) (0)
We-P12:292 Hepatic apolipoprotein-A5 MRNA expression decreases with weight loss in morbidly obese subjects with non-alcoholic fatty liver disease (2006) (0)
Acute phase reaction after liver transplantation: Cytokines and their products (1990) (0)
Alpha‐1‐antitrypsin deficiency related liver disease in heterozygous risk allele carriers: A red herring? (2019) (0)
Dendritic Cells and Th Cells B Lymphocyte-Derived IL-16 (2000) (0)
The complement system is involved in human IBD and interacts with commensal bacteria (2018) (0)
A role of autophagy in diet-induced metabolic enteritis (2022) (0)
LBP-32-The Natural History of Ferroportin Disease-First Results of the International, Multicenter EASL non-HFE Registry (2019) (0)
Polyunsaturated fatty acids in a Western diet trigger TLR2-dependent Crohn’s-like enteritis in mice (2021) (0)
Ethanol dampens IL-37 expression in liver tissue (2018) (0)
Increased Adiposity and Colorectal Cancer (2013) (0)
Sa461 THE INFLAMMATORY BOWEL DISEASE – DISTRIBUTION, CHRONICITY, ACTIVITY (IBD-DCA) SCORE IS A NEW PROMISING INDEX FOR HISTOLOGIC ACTIVITY ASSESSMENT IN ULCERATIVE COLITIS AND CROHNS DISEASE (2021) (0)
Akkermansia muciniphila tend to influence experimental non-alcoholic steatohepatitis (2017) (0)
P106 Active macrophage migration inhibitory factor (MIF) is a previously unrecognized isoform of MIF and a potential new biomarker for inflammatory bowel diseases (2013) (0)
Neurodegenerative patterns in Wilson disease with hepatic or neurological manifestation assessed by morphometric magnetic resonance imaging (2020) (0)
NAD immunometbolism drives intestinal inflammation and colitis-associated tumorigenesis (2017) (0)
Comparison of heterozygous alpha-1 antitrypsin deficiency in unselected patients with liver cirrhosis and transplant recipients with the general population and liver donors (2017) (0)
Interferon-alpha decreases leptin synthesis in murine adipocytes (2001) (0)
Autosomal Dominant Familial Intestinal Varicosis and Polyposis coli is associated with Pathogenic Variants in NKX2.3 (2021) (0)
Highlights of UEG Week 2017, Barcelona (2016) (0)
Clinical Effectiveness of Minimal and Atoxic Doses of Interferon Alpha for Treatment of Hairy Cell Leukemia1 (1987) (0)
P068 Polyunsaturated fatty acid excess fuels pro-inflammatory transcriptional networks in GPX4 deficient intestinal epithelial cells (2023) (0)
Splenic iron deficiency is characteristic for HFE-associated hemochromatosis (2018) (0)
[Obituary for Prof. Dr. Herbert Lochs (1946-2015) ]. (2015) (0)
Effect of weight loss on heme oxygenase-1 tissue expression. (2017) (0)
Phenotypic alteration of leukemic hairy cells upon interferon-alpha treatment in vitro (1986) (0)
The Natural History of Ferroportin Disease – First Results of the International, Multicenter non-HFE Registry (2019) (0)
Diet in alcohol withdrawal - coffee consumption is associated with reduced risk of alcohol-induced liver fibrosis and steatosis (2021) (0)
Chest pain after gastrointestinal endoscopic examination. (2008) (0)
Low splenic iron is characteristic of HFE-associated hemochromatosis (2018) (0)
Hepatitis C virus NS3 protein upregulates interleukin-18 in dendritic cells (2000) (0)
Polyunsaturated fatty acids fuel intestinal inflammation in GPX4 deficient hosts (2019) (0)
Impact of bile acids on immunometabolic parameters after LAGB (2016) (0)
Lipocalin 2 protects from colonic inflammation and tumorigenesis through its microbiota modulating properties Short title : Lcn 2 in intestinal inflammation (2016) (0)
Interferon-alpha augments interleukin-18 release from macrophages, but diminishes IL-18 production in dendritic cells (2000) (0)
Subject Index Vol. 30, Suppl. 1, 2012 (2012) (0)
Genetic Crohn’s disease risk instigates epithelial stress cross-talk which drives enteritis in mice (2022) (0)
Transferrin: a predictor of survival in early stage liver cirrhosis (2017) (0)
P302 Precision medicine for a case with monogenic inflammatory bowel disease (2023) (0)
Mammalian Intracellular Dickkopf1 Couples Proteostasis with Inflammation (2021) (0)
[In Process Citation]. (2016) (0)
Association of hepatic Meteorin-like and Krüppel-like factor 3 with weight loss after laporoscopic adjustable gastric banding (2021) (0)
Interferon-alpha therapy and the IL-18 pathway in chronic hepatitis C patients: IFN-alpha therapy enhances circulating IL-18 binding protein levels (2001) (0)
[Does the determination of serum neopterin secure blood transfusion?]. (1992) (0)
Dickkopf1 fuels inflammatory cytokine responses (2022) (0)
Gut-Liver Interactions: Full of New Excitements (2016) (0)
S05ALCOHOL AND INFLAMMATIONS05.1THE ROLE OF CYTOKINES IN ALCOHOLIC STEATOHEPATITIS (2011) (0)
Acute Effects of Recombinant IFN-γ on White Blood Cell Counts and Lymphocyte Subsets in the Peripheral Blood of Cancer Patients (1990) (0)
Author Correction: Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH (2021) (0)
Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk – A Retrospective Cohort Study (2016) (0)
Restoration of low adipose PNPLA3 concentrations after bariatric surgery (2015) (0)
Bariatric surgery prevents carotid wall thickness progression (2022) (0)
Circulating interleukin-18 levels are elevated in liver cirrhosis (2000) (0)
Oxygenation Performance of Different Non-Invasive Devices for Treatment of Decompression Illness and Carbon Monoxide Poisoning (2022) (0)
Diagnostic and prognostic accuracy of fibroscan and FIB-4 in hyperferritinemia and hemochromatosis (2019) (0)
Chemokine expression in non-alcoholic steatohepatitis (2003) (0)
A cellular disease model for autosomal dominant ferroportin gene mutations (2019) (0)
IFN-alpha therapy increases circulating leptin levels in hepatitis C patients: A possible link to IFN-induced cachexia (2000) (0)
Cancer in inflammatory bowel disease: frequency and clinical presentation (2009) (0)
Elevated levels of soluble interleukin-1 receptor type I, but not soluble interleukin-1 receptor type II in patients with chronic liver disease (2000) (0)
Hepatocyte growth factor fails to modulate cytokine synthesis in human mononuclear cells (1998) (0)
Malignant peritoneal Mesothelioma: prolonged unexplained CRP" – A case series (2019) (0)
The role of prophylactic treatment with A. muciniphila in the acute alcoholic liver disease (2016) (0)
Analysis of survival and influence of genetic modifiers in HFE- and non-HFE-associated iron overload (2020) (0)
Annual meeting of the Austrian society of hematology and oncology Feldkirch, September 22–24, 1986 abstracts (2004) (0)
497 ER Stress Transcription Factor XBP1 Regulates NfκB Activation in Intestinal Epithelial Cells (2009) (0)
WITHDRAWN: Cytokines and fatty liver diseases (2018) (0)
Plasma levels of soluble Fas during treatment of chronic hepatitis C patients with interferon alpha. (1999) (0)
Therapeutic modulation of the liver immune microenvironment. (2023) (0)
Letter of Thanks for UEG Week 2019 Reviewers (2019) (0)
Dietary-derived ω-3 and ω-6 polyunsaturated fatty acids induce metabolic enteritis as a fuel of Crohn’s disease (2021) (0)
Reflecting on a highly successful UEG Week 2016 (2016) (0)
Response to “Non‐alcoholic fatty liver disease and pharmacological options” (2010) (0)
Transmission of oral microbiota to the biliary tract during endoscopic retrograde cholangiography (2023) (0)
Risk factors for primary poor function in liver transplantation: a retrospective single centre analysis (2019) (0)
Liver and heart fibrosis develops simultaneously in patients with alcohol use disorder - a preliminary report of the HALFWAY study (2021) (0)
299 Autonomic and endothelial interaction with functional capacity in patients with dilated cardiomyopathy and optimal neuro‐humoral treatment (2006) (0)
[Adalimumab for the treatment of adult Crohn's disease--update of a consensus report by the Working Group Inflammatory Bowel Disease of the Austrian Society of Gastroenterology and Hepatology]. (2013) (0)
FRI-443-Non-invasive fibrosis assessment in hyperferritinemia and hemochromatosis (2019) (0)
Liver transplantation after successful downstaging of a locally advanced hepatocellular carcinoma with systemic therapy. (2023) (0)
Interferon alpha regulates interleukin-16 secretion in peripheral blood mononuclear cells via activation of caspase 3 (2000) (0)
IFIH1-deficiency promotes tumor development in the intestine (2019) (0)
The PNPLA3 G-allele is common in patients with HCC but does not affect tumor characteristics and tumor biology (2020) (0)
Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study (2019) (0)
Adalimumab for the Treatment of Adult Crohn's Disease - Update of a Consensus Report by the Working Group Inflammatory Bowel Disease of the Austrian Society of Gastroenterology and Hepatology. (2013) (0)
Author Index / Subject Index (2013) (0)
The impact of COVID-19 on liver transplantation programs in Austria (2022) (0)
Survival in HFE hemochromatosis: influence of polymorphisms in HSD17B13, GNPAT, and PCSK7 (2020) (0)
Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis. (2023) (0)
NAFLD: a multisystem disease requiring a multidisciplinary and holistic approach (2021) (0)
Human liver microbiota modeling strategy at the early onset of fibrosis (2020) (0)
The role of inhibitors of wnt signaling in cardiovascular events (2016) (0)
Poster PresentationsP029 A NATIONWIDE MULTICENTER STUDY ON VENOUS THROMBOEMBOLISM IN INFLAMMATORY BOWEL DISEASE (IBD) (2008) (0)
Interleukin-11 plays a key role in human and mouse alcohol-related liver disease (2021) (0)
DEFINING THE ROLE OF LIPOCALIN 2/LCN2 IN LIVER REGENERATION: 3072 (2010) (0)
295 Biliary leakage of fluorescent bile acids in MDR2 knockout mice: Evidence for a critical role of bile duct leakage in the pathogenesis of sclerosing cholangitis (2004) (0)
Prevalence of likely pathogenic variants in iron-related genes in patients with unexplained hepatic iron overload (2022) (0)
Hypophosphatemia after Treatment of Iron Deficiency with Intravenous Ferric Carboxymaltose or Iron Isomaltoside - A Systematic Review and Meta-Analysis (2020) (0)
O01 Transcription Factor XBP1 Regulates Paneth Cell Function and Inflammation in the Intestine (2007) (0)
Pulling the plug- NAD energy depletion as a novel treatment strategy in IBD (2014) (0)
Determinants of exercise capacity in dilated cardiomyopathy: a prospective, explorative cohort study (2012) (0)
No inflammation without energy: Inhibition of PBEF/NAMPT/Visfatin as a potential new treatment strategy in inflammatory bowel diseases (2016) (0)
Fulminant Liver Failure and Impaired hepatitis A virus clearance (2018) (0)
P085 Paneth cells translate dietary lipid exposure into gut inflammation (2022) (0)
Long-term life history predicts current elderly gut microbiome (2021) (0)
Elevated levels of soluble interleukin-1 receptor type I, but notsoluble interleukin-1 receptor type II in patients with chronicliver disease (2000) (0)
Infliximab targets mucosal inflammatory cells, resulting in histological and endoscopic healing in patients with Crohn's disease (2003) (0)
Patient motives in emergency departments – evidence from Tyrol (2017) (0)
Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis (2022) (0)
P006 The therapeutic potential of the pharmacological inhibition of PBEF/NAMPT/Visfatin in inflammatory bowel disease (2014) (0)
Paneth cell GPX4 protects from PUFA induced metabolic gut inflammation (2022) (0)
Liver Metastasis in solitary fibrous tumors (Hemangioperizytoma) – A case series (2019) (0)
P695 Does anticoagulation treatment increase the rate of major bleeding complications in patients with IBD and venous thromboembolism (2018) (0)
Identification and characterization of patients being exposed to computed-tomography associated radiation-doses above 100 mSv in a real-life setting. (2022) (0)
Using Infodemiology Metrics to Assess Public Interest in Liver Transplantation: Google Trends Analysis (Preprint) (2020) (0)
Visfatin in the immunopathogenesis of liver disease (2006) (0)
Low serum ceruloplasmin concentration is common in patients with cirrhosis and a MELD independent predictor of liver transplantation or death (2019) (0)
Interleukin-5-induced thrombopoietin mediates inflammation-associated thrombocytosis (2001) (0)
7 ER stress transcription factor Xbp1 suppresses intestinal tumourigenesis (2013) (0)
P034 A dietary fibre intervention shapes the microbiome towards an anti-inflammatory tone (2019) (0)
Letter of Thanks for UEG Week 2019 Reviewers. (2019) (0)
Lipid peroxidation of polyunsaturated fatty acids triggers a pro-inflammatory cytokine response in intestinal epithelial cells (2019) (0)
Reply (2019) (0)
Evaluation of the clinical impact of the Ceruloplasmin variant p. Thr551Ile in liver cirrhosis (2022) (0)
Clinical nephrology / Glomerulonephritis (2011) (0)
Molecular mechanisms of hypophosphatemia after intravenous iron therapy (2022) (0)
S1111 Increased Risk of Recurrent Venous Thromboembolism in Inflammatory Bowel Disease (2009) (0)
Innate Immunity in Gastrointestinal Disorders: Basic and Therapeutic Concepts: Falk Symposium 181, Munich, February 2012 (2012) (0)
The intestinal microbiota fuelling metabolic inflammation (2019) (0)
Impact of COVID-19 on liver transplantation in Austria (2022) (0)
CD4 monoclonal antibody VIT4 in human alloimmune response in vitro and in vivo. (1996) (0)
Akkermansia muciniphila protects from experimental alcoholic liver disease (2015) (0)
Impact of preoperative anemia, iron-deficiency and inflammation on survival after colorectal surgery—A retrospective cohort study (2022) (0)
Subject Index Vol. 34, Suppl. 1, 2016 (2016) (0)
The Kinase Inhibitor Imatinib Mesylate Potently Inhibits TNF-α Production by Myeloid Cells and Prevents T-Cell-Mediated Hepatic Injury in Mice. (2004) (0)
Crohn's disease (CD) derived intestinal organoids as a model to study inflammation emanating from the intestinal epithelium (2019) (0)
IFIH1-deficiency results in a cell-type specific alteration of autophagic activity in response to S. typhimurium (2017) (0)
A gut bacterium tackles atherosclerosis (2022) (0)
Interferon alpha regulates interleukin-16 secretion in peripheral blood mononuclear cells of hepatitis C patients via activation of caspase 3 (2000) (0)
Alpha-1 antitrypsin administration ameliorates experimental acute alcoholic liver disease (2018) (0)
The novel adipocytokine visfatin is activated in inflammatory bowel disease (2006) (0)
Minimal, neopterin-guided doses of alpha interferon are clinically effective and atoxic in hairy cell leukemia (1986) (0)
THU-256-Alpha-1 antitrypsin ameliorates experimental alcoholic liver disease and predicts patient outcome (2019) (0)
Reduced serum ceruloplasmin concentration is common in patients with cirrhosis and a NaMELD independent predictor of transplantation or death (2018) (0)
Clinical presentation of venous thromboembolism in inflammatory (2013) (0)
S1911 Bariatric Surgery Ameliorates Non-Alcoholic Fatty Liver Disease By Switching the Adipocytokine Profile to a Protective State (2008) (0)
[Diagnosis and therapeutic strategies in pneumonia in childhood]. (1989) (0)
Endotoxemia is not increased after TIPS implantation (2000) (0)
Reply to Gostner and Fuchs. (2019) (0)
Ceruloplasmin knockout mice as a disease model for aceruloplasminemia (2018) (0)
Interferon alpha therapy decreases circulating interleukin-18 levels in hepatitis C patients (2000) (0)
Heterogenous Progenitor Sensitivity to Various Cytokines in Patients with Myeloproliferative Disorders; Correlation of In Vitro Interferon-α Sensitivity with the Clinical Responsiveness to Recombinant Interferon-α (1990) (0)
700 The novel adipokine visfatin is involved in the pathogenesis of NAFLD (2006) (0)
UEG Week 2018 Vienna: Topics and highlights (2017) (0)
Changing the dietary composition improves inflammation but not adipocyte thermogenesis in diet-induced obese mice. (2021) (0)
Liver fibrosis might drive fibrogenesis in the heart in early alcoholic liver disease (2022) (0)
Maintenance of Telomere Length in Peripheral Blood CD4 + CD25 + Regulatory T-Cells of Cancer Patients Despite Active Proliferation. (2005) (0)
MICROBIOME IN LIVER DISEASES: UPDATE FROM A CLINICAL PERSPECTIVE (2020) (0)
Blood-Derived Dendritic Cells Attract Immature and Arrest Mature Cutting Edge: Peripheral Neuropeptides (2013) (0)
Gut microbiome, liver immunology, and liver diseases (2020) (0)
Effects of pronounced and sustained weight loss induced by bariatric surgery on PCSK-9 plasma concentrations (2015) (0)
Adipocyte fatty acid-binding protein – a biomarker associated with the metabolic syndrome and/or an indicator of weight change? (2007) (0)
Alpha 1 antitrypsin ameliorates experimental alcoholic liver disease and determines patient outcome (2019) (0)
Title Page / List of Contents / Preface (2010) (0)
ALCOHOLIC HEPATITIS: 334 (2004) (0)
Comparison of Heterozygous Alpha-1 Antitrypsin Deficiency in Patients with Liver Cirrhosis and Transplant Recipients with the General Population and Liver Donors (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Herbert Tilg?

Herbert Tilg is affiliated with the following schools:

University of Innsbruck
Medical University of Vienna
Medical University of Innsbruck
University of Salzburg
University of Vienna